MX2017015811A - Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). - Google Patents
Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).Info
- Publication number
- MX2017015811A MX2017015811A MX2017015811A MX2017015811A MX2017015811A MX 2017015811 A MX2017015811 A MX 2017015811A MX 2017015811 A MX2017015811 A MX 2017015811A MX 2017015811 A MX2017015811 A MX 2017015811A MX 2017015811 A MX2017015811 A MX 2017015811A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- antigen
- antibody
- binding portion
- binds specifically
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 101100441540 Xenopus laevis cxcr4-a gene Proteins 0.000 title 1
- 101100441541 Xenopus laevis cxcr4-b gene Proteins 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 3
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 abstract 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 abstract 3
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 abstract 2
- 108050006947 CXC Chemokine Proteins 0.000 abstract 1
- 102000019388 CXC chemokine Human genes 0.000 abstract 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562174931P | 2015-06-12 | 2015-06-12 | |
| PCT/US2016/037207 WO2016201425A1 (en) | 2015-06-12 | 2016-06-13 | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017015811A true MX2017015811A (es) | 2018-04-10 |
Family
ID=56194616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017015811A MX2017015811A (es) | 2015-06-12 | 2016-06-13 | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180179282A1 (OSRAM) |
| EP (1) | EP3307778A1 (OSRAM) |
| JP (1) | JP2018516969A (OSRAM) |
| CN (1) | CN108026173A (OSRAM) |
| BR (1) | BR112017026189A2 (OSRAM) |
| CA (1) | CA2989144A1 (OSRAM) |
| EA (1) | EA201792522A1 (OSRAM) |
| MX (1) | MX2017015811A (OSRAM) |
| WO (1) | WO2016201425A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101607288B1 (ko) * | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| KR102702287B1 (ko) * | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CA3008272A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3393468B1 (en) | 2015-12-22 | 2022-09-14 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
| EP3405203A4 (en) * | 2016-01-22 | 2019-07-24 | X4 Pharmaceuticals, Inc. | METHOD FOR THE TREATMENT OF CANCER |
| JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置する方法 |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| CA3027498A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| CA3045302A1 (en) * | 2016-11-29 | 2018-06-07 | Health Research, Inc. | Methods and compositions for cancer therapy |
| EP3600395A4 (en) * | 2017-03-23 | 2021-05-05 | The General Hospital Corporation | BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE |
| TWI734027B (zh) * | 2017-09-18 | 2021-07-21 | 泰宗生物科技股份有限公司 | 用於治療癌症之組合物 |
| CN113150068B (zh) * | 2017-09-20 | 2023-04-04 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| CN111465613A (zh) * | 2017-11-07 | 2020-07-28 | X4 制药有限公司 | 癌症生物标志物及其使用方法 |
| ES2973728T3 (es) * | 2018-03-13 | 2024-06-24 | Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz | Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US12291570B2 (en) * | 2018-10-17 | 2025-05-06 | Biolinerx Ltd. | Treatment of metastatic pancreatic adenocarcinoma |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US12497439B2 (en) | 2019-01-07 | 2025-12-16 | Thomas Jefferson University | Multi-functional fusion proteins and uses thereof |
| CA3133460A1 (en) * | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals, Inc. | METHODS OF TREATING NEUTROPENIA |
| AR129061A1 (es) | 2022-04-13 | 2024-07-10 | Genentech Inc | Composiciones farmacéuticas de mosunetuzumab y métodos de uso |
| AU2023253705A1 (en) | 2022-04-13 | 2024-10-17 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of therapeutic proteins and methods of use |
| TW202400659A (zh) * | 2022-05-04 | 2024-01-01 | 美商詹努克斯治療有限公司 | 經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法 |
| CN115487146B (zh) * | 2022-10-28 | 2023-07-18 | 宁夏医科大学 | 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用 |
| CN120282799A (zh) * | 2022-12-07 | 2025-07-08 | 宜明昂科生物医药技术（上海）股份有限公司 | 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法 |
| CN120813375A (zh) * | 2023-01-30 | 2025-10-17 | 凯玛布有限公司 | 抗体 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008018641A1 (en) | 2006-08-11 | 2008-02-14 | Ono Pharmaceutical Co., Ltd. | Monoclonal antibodies against stromal derived factor-1 (sdf-1) |
| AR063086A1 (es) * | 2006-10-02 | 2008-12-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y usos de los mismos |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
| KR20100133012A (ko) | 2008-05-14 | 2010-12-20 | 일라이 릴리 앤드 캄파니 | 항-ｃｘｃｒ4 항체 |
| US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| WO2013013025A2 (en) | 2011-07-20 | 2013-01-24 | Medimmune Limited | Anti-cxcr4 antibodies and methods of use |
| MX357100B (es) | 2011-11-09 | 2018-06-26 | Bristol Myers Squibb Co | Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4. |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR102702287B1 (ko) | 2012-05-15 | 2024-09-04 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| KR102410078B1 (ko) | 2012-05-31 | 2022-06-22 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| EP3027653A2 (en) | 2013-08-02 | 2016-06-08 | Pfizer Inc | Anti-cxcr4 antibodies and antibody-drug conjugates |
| JP2016527303A (ja) * | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害 |
-
2016
- 2016-06-13 JP JP2017564421A patent/JP2018516969A/ja not_active Withdrawn
- 2016-06-13 EA EA201792522A patent/EA201792522A1/ru unknown
- 2016-06-13 EP EP16731754.4A patent/EP3307778A1/en not_active Withdrawn
- 2016-06-13 MX MX2017015811A patent/MX2017015811A/es unknown
- 2016-06-13 WO PCT/US2016/037207 patent/WO2016201425A1/en not_active Ceased
- 2016-06-13 BR BR112017026189A patent/BR112017026189A2/pt not_active IP Right Cessation
- 2016-06-13 CN CN201680047043.2A patent/CN108026173A/zh active Pending
- 2016-06-13 CA CA2989144A patent/CA2989144A1/en not_active Abandoned
- 2016-06-13 US US15/735,055 patent/US20180179282A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016201425A9 (en) | 2017-01-19 |
| EA201792522A1 (ru) | 2018-05-31 |
| BR112017026189A2 (pt) | 2018-08-14 |
| US20180179282A1 (en) | 2018-06-28 |
| CA2989144A1 (en) | 2016-12-15 |
| JP2018516969A (ja) | 2018-06-28 |
| EP3307778A1 (en) | 2018-04-18 |
| WO2016201425A1 (en) | 2016-12-15 |
| CN108026173A (zh) | 2018-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017015811A (es) | Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4). | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MX2019008207A (es) | Métodos para tratar el cáncer con anticuerpos anti-pd-1. | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| EA201891495A1 (ru) | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| PH12018500174A1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| MX2016014753A (es) | Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno. | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| EP4406554A3 (en) | Anti-cd3 antibody formulations | |
| MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| EP4609915A3 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| EA201892541A1 (ru) | Гуманизированные анти-il-1r3 антитела | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use |